CD8A and neoplasm: To address these issues, we adoptively transferred OT‐I cells into Thy1.1 congenic C57Bl/6 mice bearing 1‐, 7‐, or 14‐day‐old B16‐cOVA or D5.1G4‐cOVA tumors so that we could evaluate the differentiation of tumor Ag‐specific CD8+ T cells shortly after tumor challenge (Day 1) as well as in response to established tumors in the context of both TFLN (Day 7 B16‐cOVA, Day 7 and Day 14 D5.1G4‐cOVA) and TILN (Day 14 B16‐cOVA).